RxSight, Inc. (NASDAQ:RXST) Holdings Decreased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC reduced its holdings in RxSight, Inc. (NASDAQ:RXST) by 51.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,474 shares of the company’s stock after selling 1,572 shares during the period. Tower Research Capital LLC TRC’s holdings in RxSight were worth $59,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. RiverPark Advisors LLC increased its stake in shares of RxSight by 70.0% in the fourth quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock worth $27,000 after acquiring an additional 275 shares during the last quarter. Amalgamated Bank raised its stake in shares of RxSight by 7.7% during the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock worth $167,000 after purchasing an additional 298 shares in the last quarter. HighTower Advisors LLC lifted its holdings in shares of RxSight by 7.3% during the 3rd quarter. HighTower Advisors LLC now owns 13,256 shares of the company’s stock valued at $369,000 after buying an additional 899 shares during the last quarter. BluePath Capital Management LLC bought a new stake in shares of RxSight in the 3rd quarter valued at approximately $32,000. Finally, Swiss National Bank raised its position in RxSight by 2.9% during the fourth quarter. Swiss National Bank now owns 45,700 shares of the company’s stock valued at $1,843,000 after acquiring an additional 1,300 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight Trading Up 0.9 %

RXST traded up $0.49 on Monday, hitting $53.26. 423,365 shares of the stock traded hands, compared to its average volume of 427,085. The business has a fifty day moving average price of $52.55 and a two-hundred day moving average price of $42.14. RxSight, Inc. has a 52 week low of $17.59 and a 52 week high of $58.21. The firm has a market capitalization of $1.98 billion, a PE ratio of -37.24 and a beta of 1.22.

RxSight (NASDAQ:RXST) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.10. The business had revenue of $28.58 million for the quarter, compared to analysts’ expectations of $28.60 million. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. On average, equities research analysts forecast that RxSight, Inc. will post -0.94 EPS for the current fiscal year.

Insider Activity

In related news, Director William J. Phd Link sold 28,250 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $49.67, for a total value of $1,403,177.50. Following the completion of the transaction, the director now owns 24,248 shares of the company’s stock, valued at $1,204,398.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other RxSight news, Director William J. Phd Link sold 28,250 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $49.67, for a total transaction of $1,403,177.50. Following the completion of the transaction, the director now directly owns 24,248 shares in the company, valued at $1,204,398.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bakker Juliet Tammenoms bought 4,000 shares of RxSight stock in a transaction dated Monday, February 12th. The stock was purchased at an average price of $50.38 per share, for a total transaction of $201,520.00. Following the purchase, the director now directly owns 25,840 shares in the company, valued at approximately $1,301,819.20. The disclosure for this purchase can be found here. In the last three months, insiders have sold 94,869 shares of company stock worth $4,771,244. Corporate insiders own 21.13% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on RXST. Stifel Nicolaus increased their price target on shares of RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Oppenheimer boosted their price target on RxSight from $54.00 to $61.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price objective on shares of RxSight in a report on Thursday, April 11th. Finally, JPMorgan Chase & Co. raised their target price on shares of RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight presently has an average rating of “Buy” and a consensus price target of $49.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.